Predicting the outcome of COVID-19 infection in kidney transplant recipients.
Acute Kidney Injury
/ etiology
Adult
Age Factors
COVID-19
/ blood
Creatinine
/ blood
Critical Care
Female
Graft Survival
/ physiology
Hospital Mortality
Humans
Kidney Transplantation
Length of Stay
Lymphocyte Count
Male
Middle Aged
Myocardial Ischemia
/ complications
Renal Replacement Therapy
Respiration, Artificial
Retrospective Studies
Risk Factors
SARS-CoV-2
Serum Albumin
/ metabolism
Transplant Recipients
Treatment Outcome
Turkey
/ epidemiology
COVID-19
Kidney transplantation
Registry
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
19 03 2021
19 03 2021
Historique:
received:
05
10
2020
accepted:
04
03
2021
entrez:
20
3
2021
pubmed:
21
3
2021
medline:
2
4
2021
Statut:
epublish
Résumé
We aimed to present the demographic characteristics, clinical presentation, and outcomes of our multicenter cohort of adult KTx recipients with COVID-19. We conducted a multicenter, retrospective study using data of patients hospitalized for COVID-19 collected from 34 centers in Turkey. Demographic characteristics, clinical findings, laboratory parameters (hemogram, CRP, AST, ALT, LDH, and ferritin) at admission and follow-up, and treatment strategies were reviewed. Predictors of poor clinical outcomes were analyzed. The primary outcomes were in-hospital mortality and the need for ICU admission. The secondary outcome was composite in-hospital mortality and/or ICU admission. One hundred nine patients (male/female: 63/46, mean age: 48.4 ± 12.4 years) were included in the study. Acute kidney injury (AKI) developed in 46 (42.2%) patients, and 4 (3.7%) of the patients required renal replacement therapy (RRT). A total of 22 (20.2%) patients were admitted in the ICU, and 19 (17.4%) patients required invasive mechanical ventilation. 14 (12.8%) of the patients died. Patients who were admitted in the ICU were significantly older (age over 60 years) (38.1% vs 14.9%, p = 0.016). 23 (21.1%) patients reached to composite outcome and these patients were significantly older (age over 60 years) (39.1% vs. 13.9%; p = 0.004), and had lower serum albumin (3.4 g/dl [2.9-3.8] vs. 3.8 g/dl [3.5-4.1], p = 0.002), higher serum ferritin (679 μg/L [184-2260] vs. 331 μg/L [128-839], p = 0.048), and lower lymphocyte counts (700/μl [460-950] vs. 860 /μl [545-1385], p = 0.018). Multivariable analysis identified presence of ischemic heart disease and initial serum creatinine levels as independent risk factors for mortality, whereas age over 60 years and initial serum creatinine levels were independently associated with ICU admission. On analysis for predicting secondary outcome, age above 60 and initial lymphocyte count were found to be independent variables in multivariable analysis. Over the age of 60, ischemic heart disease, lymphopenia, poor graft function were independent risk factors for severe COVID-19 in this patient group. Whereas presence of ischemic heart disease and poor graft function were independently associated with mortality.
Sections du résumé
BACKGROUND
We aimed to present the demographic characteristics, clinical presentation, and outcomes of our multicenter cohort of adult KTx recipients with COVID-19.
METHODS
We conducted a multicenter, retrospective study using data of patients hospitalized for COVID-19 collected from 34 centers in Turkey. Demographic characteristics, clinical findings, laboratory parameters (hemogram, CRP, AST, ALT, LDH, and ferritin) at admission and follow-up, and treatment strategies were reviewed. Predictors of poor clinical outcomes were analyzed. The primary outcomes were in-hospital mortality and the need for ICU admission. The secondary outcome was composite in-hospital mortality and/or ICU admission.
RESULTS
One hundred nine patients (male/female: 63/46, mean age: 48.4 ± 12.4 years) were included in the study. Acute kidney injury (AKI) developed in 46 (42.2%) patients, and 4 (3.7%) of the patients required renal replacement therapy (RRT). A total of 22 (20.2%) patients were admitted in the ICU, and 19 (17.4%) patients required invasive mechanical ventilation. 14 (12.8%) of the patients died. Patients who were admitted in the ICU were significantly older (age over 60 years) (38.1% vs 14.9%, p = 0.016). 23 (21.1%) patients reached to composite outcome and these patients were significantly older (age over 60 years) (39.1% vs. 13.9%; p = 0.004), and had lower serum albumin (3.4 g/dl [2.9-3.8] vs. 3.8 g/dl [3.5-4.1], p = 0.002), higher serum ferritin (679 μg/L [184-2260] vs. 331 μg/L [128-839], p = 0.048), and lower lymphocyte counts (700/μl [460-950] vs. 860 /μl [545-1385], p = 0.018). Multivariable analysis identified presence of ischemic heart disease and initial serum creatinine levels as independent risk factors for mortality, whereas age over 60 years and initial serum creatinine levels were independently associated with ICU admission. On analysis for predicting secondary outcome, age above 60 and initial lymphocyte count were found to be independent variables in multivariable analysis.
CONCLUSION
Over the age of 60, ischemic heart disease, lymphopenia, poor graft function were independent risk factors for severe COVID-19 in this patient group. Whereas presence of ischemic heart disease and poor graft function were independently associated with mortality.
Identifiants
pubmed: 33740915
doi: 10.1186/s12882-021-02299-w
pii: 10.1186/s12882-021-02299-w
pmc: PMC7977489
doi:
Substances chimiques
Serum Albumin
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Diagnosis (Berl). 2020 May 26;7(2):91-96
pubmed: 32352401
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
Am J Transplant. 2020 Nov;20(11):3051-3060
pubmed: 32654332
PLoS One. 2020 May 11;15(5):e0233147
pubmed: 32392262
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
J Heart Lung Transplant. 2020 May;39(5):408-409
pubmed: 32253113
Am J Transplant. 2020 Jul;20(7):1947-1948
pubmed: 32243698
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Kidney Int. 2020 Jun;97(6):1083-1088
pubmed: 32354634
Kidney Int. 2020 Dec;98(6):1549-1558
pubmed: 32853631
J Intensive Care. 2020 May 24;8:36
pubmed: 32483488
Kidney Int. 2000 Jan;57(1):307-13
pubmed: 10620213
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
J Med Virol. 2020 Oct;92(10):1787-1788
pubmed: 32297987
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Am J Transplant. 2020 Jul;20(7):1941-1943
pubmed: 32233067
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Am J Transplant. 2020 Jul;20(7):1875-1878
pubmed: 32198834
Am J Transplant. 2020 Jul;20(7):1819-1825
pubmed: 32351040
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
Am J Transplant. 2020 Nov;20(11):3140-3148
pubmed: 32649791
Am J Transplant. 2020 Jul;20(7):1768-1772
pubmed: 32090448
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779